Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells

Eva M. Weissinger1, Sylvia Borchers1, Anna Silvani2, Elena Provasi2, Marina Radrizzani2, Irene K. Beckmann1, Claudia Benati2, Joerg Schmidtke4, Wolfgang Kuehnau4, Patrick Schweier1, Susanne Luther4, Ivonne Fernandez-Munoz1, Gernot Beutel1, Fabio Ciceri3, Chiara Bonini3, Arnold Ganser1, Bernd Hertenstein1,5 and Michael Stadler1

1 Laboratory for Transplantation Biology, Department of Hematology/Hemostasis/Oncology/Stem Cell Transplantation, Hannover Medical School, Hannover, Germany, 2 MolMed, Milano, Italy, 3 Institute of Human Genetics, Hannover Medical School, Hannover, Germany, 4 Cancer Immunotherapy and Gene Therapy Program, San Raffaele Hospital, Milano, Italy, 5 Department of Hematology/Oncology, Klinikum Bremen-Mitte, Bremen, Germany

Allogeneic stem cell transplantation (allo-HSCT) is one of the curative treatments for hematologic malignancies, but is hampered by severe complications, such as acute or chronic graft-versus-host-disease (aGvHD; cGvHD) and infections. CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-TK and the truncated ΔLNGFR for selection of transduced cells. Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors). Nine patients were included in the first trial (MHH; 2002 until 2007), two were included in TK007 (2005–2009) and six serves as a control group for outcome after haploidentical transplantation without HSV-TK-transduced DLI. Three patients developed acute GvHD, two had grade I of the skin, one had aGvHD on day +131 (post-HSCT; +89 post-HSV-TK DLI) grade II, which was successfully controlled by ganciclovir (GCV). Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. Functionality of HSV-TK gene expressing T-cells was shown by loss of bcr-able gene expression as well as by control of cytomegalovirus-reactivation. To date, six patients have relapsed and died, two after a second hematopoietic stem cell transplantation without T-cell depletion or administration of unmodified T-cells. Eleven patients (seven post-HSV-TK DLI) are alive and well to date.

Keywords: gene transfer, horizontal, gene therapy, proteomics data, allogeneic stem cell transplantation, graft vs. host disease
Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is applied successfully to the treatment of many hematopoietic malignancies, but remains limited by severe acute graft-versus-host-disease (aGvHD). Despite prophylactic treatment of the patients with immunosuppressive drugs after allo-HSCT, GvHD is still associated with non-relapse mortality (NRM) and contributes around 25% of NRM. (Mavroudis et al., 1998) T-cell depletion of the graft by CD34-enrichment has been found to be the most effective method to prevent GvHD, but this leads to an increased risk of leukemic relapse in about 80% of patients (Horowitz et al., 1990; Gratwohl, 1994). Leukemic relapse can be treated by donor leukocyte infusion (DLI; Hertenstein et al., 1993; Kolb et al., 1995; Massenkeil et al., 2003), providing evidence for an immunological graft-versus-leukemia effect (GVL). Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD (Kolb, 2008). Acute GvHD contributes significantly to non-relapse morbidity and mortality (NRM), thus prevention or control of this severe complication is necessary.

T-cells are optimal targets for retroviral gene transfer and stability of transduced T-cells has been shown even for several years (Herve et al., 1992; Mavilio et al., 1994; Tiberghien, 1994; Contassot et al., 2000; Weissinger et al., 2000; Ciceri et al., 2009; Borchers et al., 2011). The expression of suicide genes has been shown to be effective to control GvHD, while retaining the positive effects of T-cells like GvL-activity (Bonini et al., 1997; Bondanza et al., 2006; Ciceri et al., 2009; Borchers et al., 2011). Clinical trials with HSV-TK transduced donor T-cells were initiated early in France, Italy and Germany and have been previously published (Bonini et al., 1997; Ciceri et al., 2009; Borchers et al., 2011). Transduced donor T-cells were transfused either immediately after hematopoietic stem cell transplantation (HSCT) on day 0 (Contassot et al., 2000; Ferrand et al., 2000), on day +40 (Ciceri et al., 2009) or after day +60 (Borchers et al., 2011). Eight patients from the first NGFR-HSV-TK-studies developed acute (n = 6) or chronic GvHD (n = 2), which resolved after treatment with GCV alone in seven of eight patients. Immunization against HSV-TK epitopes was observed in one patient at MHH and led to premature elimination of transduced T-cells (Borchers et al., 2011). The chance to get immunized strictly depended on the presence of an active immune system at the time of transduction of transduced T-cells (Traversari et al., 2007). At Hannover proteomic monitoring was added to predict pending, severe aGvHD to patients included after 2005 [10 of 12 acute myeloid leukemia (AML) patients; Weissinger et al., 2007, 2013]. Here, we analyzed the long term outcome of all patients treated at MHH with genetically modified T-cells and compare the outcome of mismatched transplantation in combination with prophylactic DLI to unmodified DLI-treatment of relapse.

Materials and Methods

Study Protocol

Case Description

Seventeen patients, 15 with AML and two with chronic myelogenous leukemia (CML), were transplanted from their HLA-identical (n = 9) or haploidentical (n = 8) family donors with CD34-enriched stem cells without further immunosuppression (Table 1). Eleven received transduced donor lymphocytes according to either one of the protocols (Figure 1). The clinical protocols were approved by the ethic committee of the Hannover Medical School (protocol numbers 2157 or 3644) and by the national committee for somatic gene therapy of the "Bundesärztekammer” (No 53 or No 76) and the Paul-Ehrlich-Institute (1274). In addition, both trials were registered at the German register of gene therapy trials.

Conditioning and Hematopoietic Stem Cell Transplantation

T-cells were harvested from all donors after informed consent and shipped to Milano for transduction. Eleven patients received total body irradiation (TBI; 12 Gy) and cyclophosphamide (120 mg/kg) followed by a CD34-enriched stem cell graft from matched related donors (MRDs; Table 1). Donors received G-CSF (2 × 5 µg/kg daily) for 4–5 days and blood leukocytes were collected at the Institute for Transfusion Medicine (MHH; Borchers et al., 2011). CD34-selection was performed under GMP conditions using the CliniMACS-system (Miltenyi; Bergisch Gladbach, Germany) at the Center for Cellular Therapy (former Cytonet, Hannover, Germany). At least 3.9 × 10^6/kg CD34-positive cells were transplanted on day 0, and CD34+ T-cells were usually below 1 × 10^4 cells/kg body weight (Table 1). CD34-selection was the only GvHD prophylaxis. Missing informed consent, acute GvHD grade II or more, life threatening infections, or relapse at the time of transfusion were exclusion criteria for gene therapy. Relapse and declining donor chimerism were treated with additional, non-transduced DLI (see Table 2). One patient (UPN 1505) received a second transduced DLI to treat relapse.

Description of the Retroviral Vector and the Transduction Protocol

Lymphapheresis material was obtained from 11/17 donors and shipped to MolMed (Italy) by courier for transduction. The replication-deficient, retroviral vector SFCMM-3 encodes the HSV-TK gene that confers sensitivity to GCV, and the truncated low affinity nerve-growth-factor-receptor gene (ΔLNGFR) serving as a positive selection marker and transduction protocols have been described previously (Mavilio et al., 1994; Bonini et al., 2007; Ciceri et al., 2007, 2009; Borchers et al., 2011) Briefly, cells were expanded with OKT-3 (30 ng/ml) in RPMI1640 with 5% autologous plasma and 100 U/ml IL-2 (Chiron, USA) for 72 h. Cells were transduced by spin-inoculation with
SFCM-3-supernatant twice within 24 h in the presence of 4 µg/ml protamine sulfate and expanded for 48 h. Transduction efficiencies were determined by FACS and subsequently the cells were selected using a monoclonal antibody (anti-LNGFR-antibody, Roche, Mannheim, Germany) and immunomagnetic beads (Dynabeads; Verzeletti et al., 1998). Transduced and selected cells were cryopreserved, while safety tests (as approved by the authorities) were accomplished and shipped to Hannover for transfusion (Table 1).

### Monitoring for the Presence of Transduced T Lymphocytes

Characterization and ex vivo detection of circulating transduced cells was planned at weekly for the first month 1, 2, 3, 4, 8, 12, 16, 20, 24, at 9 months, 12 months, and yearly thereafter. The follow up for three patients is now more than 12 years (Tables 2 and 3). Flow cytometry (FACS; Coulter, Germany) was performed to examine the frequency and phenotype of the transferred gene-modified T-cells in vivo using mAbs specific to LNGFR (Roche, Mannheim, Germany), CD3, CD4, and CD8 (Coulter), respectively. Immune reconstitution was analyzed for B-, T-, natural killer cells, macrophages, and monocytes.

The presence of gene modified T-cells was confirmed by polymerase chain reactions (PCRs) with primers for the HSV-TK and the LNGFR-gene, as described (Borchers et al., 2011).

### HSV-TK-Gene, Donor-Chimerism, and T-Cell Receptor (TCR)-Vβ Family Expression

Transduced cells were analyzed at above mentioned time points and yearly thereafter for the presence of HSV-TK gene expression. To increase the likelihood to detect gene modified cells,

---

**TABLE 1A | Patient clinical characteristics: all patients were transplanted with CD34-enriched donor cells from their HLA-identical siblings or haploidentical family donors.**

| Table 1: clinical data | All patients (n = 17) | All patients (n = 17) |
|------------------------|----------------------|----------------------|
| Age                    | 35 (18–63)           |                      |
| Disease                |                      | GvHD-Pro             |
| Acute (AML, ALL, sAML) | 15                   | CSA/MTX 0            |
| Chronic (MDS, MPS, CML, CLL) | 2     | CSA/MMF 1            |
| Status                 |                      | TCD 11               |
| CR 1/CP1               | 14                   | ATG, Thymo 14        |
| CR 2 or higher         | 2                    | None 3               |
| No CR (untreated, relapse, ref.) | 1 | Donor 17             |
| Conditioning           |                      | Unrelated 0          |
| Myeloablative (TBI/Cy) | 9                    | HLA-match 9          |
| RIC                    | 8                    | Matched 9            |
| Graft                  |                      | Mismatched 8         |
| PBSC                   | 17                   | Gender               |
| Bone marrow            | 1*                   | Female/male 9/8      |
| HSV-TK DLI             | 11                   | m/f donor 4          |
| None                   | 6                    | Alive 11             |

Donors’ gender and age are shown under “donor.” Transduced T-cells were transfused after day +60 or day +42 (MMRD). *PBSC (CD6-depleted) +BM.

---
TABLE 1C | Clinical characteristics, and follow-up after haplo-HSCT (MMRD) with and without HSV-TK gene transfer: patient and donor characteristics acute and chronic GvHD are summarized for two patients with HSV-TK T-cells and six control patients without gene transduced DLI.

| UPN    | Age  | Gender | Diagnosis | FAB-classification | Status | HLA-donor | Source | Conditioning | GvHD_Proph | Acute GvHD | aGvHD-days | aGvHD-grade | ChrGvHD | CGvHD-grade (days) |
|--------|------|--------|-----------|-------------------|--------|-----------|--------|--------------|------------|------------|------------|-------------|----------|-------------------|
| 1505   | 23   | f      | AML       | M4/M5             | CR 1   | MMRD      | PBPC   | Flu/Mel      | TCD        | Yes        | 131        | II          | No        |                   |
| 1550   | 25   | m      | AML       | MO               | Induction failure | MMRD     | KM+PBPC  | Flamsa(TBI)/ATG | CSA/MTX    | No         | n.a.       | n.a.        | Unknown   |                   |
| 1551   | 32   | f      | AML       | M5b              | CR 2   | MMRD      | PBPC   | Flu/Mel      | TCD        | No         | n.a.       | No          | Yes       |                   |
| 1438   | 34   | m      | AML       | M5b              | CR 1   | MMRD      | PBPC   | Flu/Mel      | TCD        | No         | n.a.       | No          | Yes       |                   |
| 1269   | 18   | m      | AML       | M5a              | CR 1   | MMRD      | PBPC   | Flu/Mel      | TCD        | ja         | 54         | I           | Yes        |                   |
| 1272   | 38   | m      | AML       | MO               | CR 1   | MMRD      | PBPC   | Bu/Cy/ATG    | CSA/MTX    | No         | n.a.       | Yes         | Limited (131) |                   |
| 1455   | 63   | m      | AML       | MO               | CR 2   | MMRD      | PBPC   | Flu/Mel      | TCD        | No         | n.a.       | Yes         | Limited (117) |                   |
| 1524   | 58   | f      | AML       | M4O              | CR 1   | MMRD      | PBPC   | Flamsa (w/o AMSA) (TBI)/ATG | CSA/MMF    | ja         | 30         | I           | No         |                   |

TABLE 1D | CMV-reactivation and immune reconstitution after MMRD-HSCT: summarizes the data after transplantation for 1505 and 1550 with respect to immune reconstitution of CMV-specific CTL.

| UPN    | Age  | Diagnosis | Tx (Tet-table) | HLA-recipient CMV+ | Donor | Days post-HSCT | CD3+/μl | CD8+/μl | CD8+/μl count OK? (≥50) | A0201 % | A0201/μl | A2402 % | A2402 % der CD3+CD8+ | Absolute number A2402/μl | All CMV+ T-Zellen/μl | EBV A0201 % | EBV A0201/μl | Comment(s) |
|--------|------|-----------|----------------|-------------------|-------|----------------|--------|--------|--------------------------|---------|---------|---------|----------------------|-----------------------|-----------------------|-----------|-----------|-----------|
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 −50   | 1301   | 517    | 673                      | Yes     | 0.22    | 1       | 0.05                 | 1                     | 1.07                  | 0         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 28    | 3      | 2      | 1                       | No      | 0.00    | 0       | 0.00                 | 0                     | 0.87                  | 0         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 55    | 27     | 5      | 13                      | No      | 0.00    | 0       | 0.00                 | 0                     | 0.42                  | 0         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 77    | 3263   | 2960   | 251                      | Yes     | 0.01    | 0       | 0.06                 | 2                     | 0.01                  | 0         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 83    | 3944   | 3549   | 315                      | Yes     | 0.01    | 0       | 0.12                 | 4                     | 0.22                  | 8         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 90    | 2071   | 1603   | 386                      | Yes     | 0.03    | 2       | 2.04                 | 33                    | 35.1                  | 29        | Clear population | Claire population |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 97    | 1629   | 1065   | 452                      | Yes     | 0.02    | 0       | 2.75                 | 29                    | 30.1                  | 19        | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 137   | 1199   | 685    | 447                      | Yes     | 0.01    | 0       | 0.02                 | 0                     | 0.07                  | 0         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 143   | 1048   | 422    | 538                      | Yes     | 0.02    | 0       | 3.01                 | 13                    | 1.92                  | 8         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 213   | 612    | 391    | 160                      | Yes     | 0.00    | 0       | 0.05                 | 0                     | 0.00                  | 0         | Prior HSCT |                   |
| 1505   | 23   | AML       | 2.2.2007       | A02/A24          | MMRD  | A02 A24 230   | 715    | 473    | 206                      | Yes     | 0.00    | 0       | 0.07                 | 0                     | 0.00                  | 0         | Prior HSCT |                   |
| 1505   | 25   | AML       | 31.5.2007      | A02       | MMRD  | A02 −29      | 542    | 232    | 238                      | Yes     | 1.70    | 4       | n.a.                 | n.a.                  | 0.12                  | 0         | Prior HSCT |                   |
| 1505   | 25   | AML       | 31.5.2007      | A02       | MMRD  | A02 32       | 23     | 16     | 2                       | No      | 1.06    | 0       | n.a.                 | n.a.                  | 0.00                  | 0         | Prior HSCT |                   |
| 1505   | 25   | AML       | 31.5.2007      | A02       | MMRD  | A02 43       | 630    | 404    | 62                       | Yes     | 0.13    | 1       | n.a.                 | n.a.                  | 0.00                  | 0         | Prior HSCT |                   |

Prior HSCT (day −29) CMV-CTL could be detected, after HSCT the patient reactivated CMV and by day +32 CMV-CTL reconstitution occurred. Shown are absolute numbers of CMV-CTL after tetramer staining with HLA-∗A02 (pp65-NLV) tetramer. Patient 1550 (PBSC-CD6-depleted+ BM) reactivated CMV on day +32 and controlled the CMV-reactivation after treatment with GCV (no transduced DLI) and upon expansion of CMV-CTL from the graft.
A summary of the results is shown in Table 3. The PCR was run on 1.2% agarose gels and analyzed. A nested PCR had been developed for the detection of HSV-TK gene (Borchers et al., 2011). RT-PCR analyses were done using 25 Vß-family specific primers, including controls for the constant region of the TCR and human ß-actin, as described (Naumov et al., 1995). RT-PCR for detection of the bcr-abl fusion transcript was performed as proposed by the BIOMED-1 nested PCR on Taqman concerted action (Van Dongen et al., 1999; Borchers et al., 2011). PCR was performed with the T3 thermocycler (Biometra). Donor chimerism was analyzed by PCR amplification of highly polymorphic short tandem repeat (PCR-STR) sequences in peripheral blood and/or bone marrow samples as described earlier (Briones and Amils, 1998).

Results

12 Years of Successful Transduced T-Cell Transfer at MHH

Seventeen patients were transplanted from MRD or mismatched related donors (MMRDs) and eleven received gene-modified donor T-cells on day +42 (n = 2) or after day +60 (n = 9) after HSCT. Clinical and demographic data are summarized in Table 1. Lymphaphereses were prepared from 11 donors and shipped to MolMed for transduction by courier. After G-CSF-stimulation peripheral blood stem cells (PBSCs) were collected and CD34+ cells were selected and transplanted on day 0. The recipient of matched related donor PBSC received conditioning treatment with total body irradiation (TBI; 12 Gy) and cyclophosphamide (120 mg) and ATG (30 mg/kg). The recipients of the mismatched related donor PBSC received conditioning with Fludarabine, Melphalan, Thiopeta, and anti-thymoglobulin (ATG; 60 mg/kg). Lymphapheresis cells were transduced with SCFMM3, and shipped to Hannover prior transfection. HSV-TK DLI (1 x 10⁷ cells/kg BW) were administered either after day +60 (MRD) or on day +42 (MMRD; 1 x 10⁶/kg BW).

Transfusion of Genetically Modified Donor Lymphocytes or Untransduced

Seven patients had residual host cells prior to DLI. In six patients donor chimerism progressively increased after DLI and full donor chimerism was obtained in three patients, thus suggesting that the infusion of genetically modified donor lymphocytes may have facilitate HSCT engraftment. In T-depleted transplantation the achievement of full chimerism is particularly difficult. In accordance with this hypothesis, expansion of transduced donor lymphocytes often preceded the improvement of donor chimerism.

ΔLNNGFR-positive cells were detected by FACS (up to 6.6% of CD3+ cells) for at least 6 months after transfusion. In two MMRD-recipients all CD3+ T-cells detected were transduced and of donor-origin, as expected. Patient UPN1505 reactivated CMV early after MMRD-HSCT. Transduced cells were transfused on day +42 from the CMV-seropositive donor and by day +77 CMV-CTL (n = 2) from the MMRD were detected (Table 1D). This was followed by an expansion of the CMV-CTL and led to the control of CMV-reactivation (Table 1D). UPN 1505 also developed aGVHD grade II (day +131; Tables 1C,D). GCV was given at 5 mg/kg body weight and as a result aGVHD was cleared. Unfortunately the patient developed relapse and died despite a second transfusion of HSV-TK transduced DLI on day +222 (Tables 1C and 2). Patient 1550 did not receive any DLI, but CMV-CTL could be detected by day +44, providing protection against CMV-reactivation. HSV-TK gene expression was analyzed until last follow-up in all patients and a summary of the data is shown Table 3. The longest follow-up for HSV-TK transduced cells was 7 years after HSCT (UPN1190), followed by 3 years (UPN914), whereas HSV-TK transduced cells were detectable for almost 2 years in another 6. One patient UPN919 lost HSV-TK gene expression after 22 months, in the absence of GCV treatment due to an immunization against transgene products (Borchers et al., 2011). Thus, seven patients had detectable levels of HSV-TK for more than 1 year after HSCT, two died prior to the first year after HSCT (Table 3). PCR for HSV-TK gene expression and donor chimerism are done yearly for all patients alive. To date, six patients have a follow up.
TABLE 2 | Summary of transduced and non-transduced DLI: peripheral blood of all patients was screened routinely for the presence of transduced cells with FACS and PCR.

| UPN | Gebdat | Age HSCT (1st and 2nd) | DLI | DLI-days-post-HSCT | Cells/kg BW |
|-----|--------|------------------------|-----|-------------------|-------------|
| 914 | 06.07.1957 | 45 | DLI(HSV-TK) | 71 | 1 × 10E7 |
| 914 | 06.07.1957 | 45 | DLI chimerism | 178 | 1 × 10E7 |
| 91A | 06.07.1957 | 45 | DLI chimerism | 249 | 1 × 10E7 |
| 91A | 06.07.1957 | 45 | DLI chimerism | 329 | 3 × 10E7 |
| 91A | 06.07.1957 | 45 | DLI chimerism | 406 | 5.3 × 10E7 |
| 919 | 03.02.1967 | 35 | DLI(HSV-TK) | 87 | 4 × 10E6 |
| 1021 | 02.12.1963 | 39 | DLI(HSV-TK) | 113 | 1.3 × 10E7 |
| 1021 | 02.12.1963 | 39 | DLI relapse | 2535 | 1.8 × 10E7 |
| 1021 | 02.12.1963 | 39 | DLI relapse | 2564 | 1.12 × 10E8 |
| 1040 | 28.12.1952 | 50 | Stemcell boost | 191 | 6 × 10E6 CD34+ |
| 1040 | 28.12.1952 | 50 | DLI(HSV-TK) | 330 | 1 × 10E7 |
| 1040 | 28.12.1952 | 53 | DLI prophylaxis | 688 | 1.03 × 10E6 |
| 1040 | 28.12.1952 | 53 | DLI prophylaxis | 304 | 5 × 10E6 |
| 1040 | 28.12.1952 | 53 | DLI prophylaxis | 339 | 1 × 10E7 |
| 1040 | 28.12.1952 | 53 | DLI relapse | 535 | 5 × 10E7 |
| 1040 | 28.12.1952 | 53 | DLI relapse | 563 | 1 × 10E8 |
| 1040 | 28.12.1952 | 53 | DLI relapse | 612 | 1.23 × 10E8 |
| 1048 | 23.01.1965 | 38 | DLI(HSV-TK) | 100 | 1.5 × 10E7 |
| 1108 | 18.02.1953 | 51 | DLI(HSV-TK) | 126 | 4 × 10E6 |
| 1159 | 23.12.1968 | 35 | DLI(HSV-TK) | 136 | 7.5 × 10E6 |
| 1190 | 10.03.1966 | 38 | DLI(HSV-TK) | 129 | 1 × 10E7 |
| 1208 | 06.12.1953 | 51 | DLI(HSV-TK) | 73 | 1.3 × 10E7 |
| 1208 | 06.12.1953 | 51 | DLI relapse | 591 | 1.8 × 10E7 |
| 1299 | 10.04.1987 | 18 | DLI relapse | 377 | 5.38 × 10E4 |
| 1299 | 10.04.1987 | 18 | DLI relapse | 405 | 1.3 × 10E5 |
| 1299 | 10.04.1987 | 18 | DLI relapse | 433 | 4.7 × 10E5 |
| 1299 | 10.04.1987 | 18 | DLI relapse | 461 | 1.27 × 10E6 |
| 1299 | 10.04.1987 | 18 | DLI relapse | 488 | 5 × 10E6 |
| 1299 | 10.04.1987 | 18 | DLI relapse | 517 | 1 × 10E7 |
| 1299 | 10.04.1987 | 18 | DLI relapse | 545 | 5.03 × 10E7 |
| 1438 | 13.10.1972 | 34 | No | na |
| 1550 | 25.04.1982 | 25 | No | na |
| 1505 | 16.12.1983 | 23 | DLI(HSV-TK) | 48 | 1 × 10E6 |
| 1505 | 16.12.1983 | 23 | DLI(HSV-TK) therapy | 222 | 1 × 10E6 |
| 1551 | 18.06.1975 | 32 | DLI(HSV-TK) | 42 | 1 × 10E6 |

The number of transduced (first DLI) and non-transduced DLI (for loss of chimerism or relapse) are shown as number of transduced cells (CD3+ cells) or as number of leukocytes transfused per kg body weight.

of more than 6 years patients, two patients had been treated 12 years ago and are both alive and well. None of the surviving patients show HSV-TK expression at last follow up (Table 3).

Discussion

Our data show the long term safety and efficacy of retroviral gene transfer in mature T-cells. The transfusion of transduced cells was tolerated well in all patients with no reported toxicities. Replication competent particles have not been detected and in general gene expression is lost after about 2 years. Ciceri et al. (2009) have recently shown that transfusion of transduced CD3+ cells after haploidentical transplantation allows for optimal expansion of transduced cells (Garin et al., 2001). Long term transgene expression for more than 1 year was observed in seven of nine patients, five had HSV-TK expressing cells for more than 1 year. Two patients transplanted from mismatched donors died prior to day +365. Efficacy of the cells had been demonstrated by control of bcr-abl positivity, donor-chimerism conversion and in the MMRD-transplanted patient 1505 acytomegalovirus-reactivation was controlled by the expansion of HSV-TK-transduced donor T-cells.

TK007 protocol called for haploidentical (MMRD) HSCT and eight patients were transplanted from haploidentical donors...
TABLE 3 | Long term follow up of PCR for TK-gene: summarizes the results obtained with PCR on HSV-TK gene expression.

| UPN  | Days post-HSCT | Days post-DLI | Years follow-up | Material for cDNA | HSV-TK PCR result | Comments |
|------|----------------|---------------|-----------------|-------------------|-------------------|----------|
| 914  | 1155           | 1084          | 3.0             | PBMCNs            | Positive          |          |
| 1048 | 791            | 691           | 1.9             | PBMCNs            | Positive          |          |
| 1048 | 1002           | 902           | 2.5             | PBMCNs            | Negative          |          |
| 1108 | 723            | 597           | 1.6             | PBMCNs            | Positive          |          |
| 1108 | 807            | 681           | 1.9             | PBMCNs            | Positive          |          |
| 1108 | 3598           | 3472          | 9.5             | CD3+              | Negative          | Alive    |
| 1159 | 365            | 229           | 0.6             | PBMCNs            | Negative          |          |
| 1159 | 640            | 504           | 1.4             | CD3+              | Negative          |          |
| 1190 | 2398           | 2269          | 6.2             | CD3+              | Negative          |          |
| 1190 | 2767           | 2638          | 7.2             | CD3+              | Positive          |          |
| 1190 | 3144           | 3015          | 8.3             | CD3+              | Negative          | Late relapse, alive |
| 1208 | 476            | 403           | 1.1             | PBMCNs            | Positive          |          |
| 1208 | 484            | 411           | 1.1             | PBMCNs            | Positive          |          |
| 1208 | 512            | 439           | 1.2             | PBMCNs            | Positive          | Relapse; re-transplantation; died |
| 1505 | 221            | 173           | 0.5             | CD3+              | Positive          |          |
| 1505 | 250            | 202           | 0.6             | CD3+              | Positive          |          |
| 1505 | 277            | 229           | 0.6             | CD3+              | Negative          | Died relapse |
| 1551 | 114            | 72            | 0.2             | CD3+              | Positive          |          |
| 1551 | 148            | 106           | 0.3             | CD3+              | Negative          |          |
| 1551 | 220            | 178           | 0.5             | CD3+              | Positive          | Died     |

(MMRD) at Hannover. Only two patients received transduced DLI, the others were observed as control group for MMRD-HSCT and HSV-TK transfer. All patients receiving transduced T-cells expressed the transgenes for at least 1 year or until last follow up, if patients died prior to day +365 (Table 3). In one patient an immunization against the transgenes had occurred thus the cells were lost earlier (Borchers et al., 2011).

We have not detected non-functional HSV-TK genes in our small patient cohort to date (Mercier-Letondal et al., 2008). A LNGFR expression as a selection marker allows rapid selection of the transduced cells, which may be favorable for the phenotype of the transduced cells, leaving the T-cell receptor repertoire of the transduced cells relatively intact (Borchers et al., 2011) as compared to more time consuming selection methods with antibiotic resistance genes.

In our studies, two of the 11 patients treated with HSV-TK transduced T-cells so far developed aGVHD grades I or II, respectively. The patient (UPN1505) had developed acute GVHD grade II and was treated successfully with GCV, thus giving a confirmation of the feasibility of the HSV-TK gene transfer for control of acute GVHD by GCV treatment. The persistence of the transduced cells over about 2 years in the majority of the patients suggests that the transduced cells were able to engraft and expand. The expansion of the transduced cells could be linked to clinical data, such as viral infections or was seen as response to declining donor chimerism, suggesting function of transduced cells. After transfusion of the transduced cells one patient reactivated CMV early after HSCT (day +20) and upon transfusion of the transduced cells the CMV-reactivation was cleared. In one patient (UPN919) HSV-TK transduced were lost after 22 months.
A low rate of immune mediated elimination of transduced cells was observed in our studies, suggesting that early add-back of TK-expressing cells is permitted, despite intrinsic immunogenicity of the viral-derived suicide gene.

In summary, the data presented here indicate that the use of SFCMM-3 transduced T-cells can be monitored in a clinical setting and is currently safe, efficient, and adequate for the proposed treatment of GvHD.

Acknowledgments

The authors thank the “Deutsche Jose Carreras Leukämie-Stiftung” for the financial support provided to this project by a grant No DJCLS-R98/11 (to AG) and to the European study group (Bonini et al. 1997) “Suicide Gene transfer in Stem Cell Transplantation” supported in part by the European Union (No: QLRT-2000-01265).

References

Bonini, C., Bondanza, A., Perna, S. K., Kaneko, S., Traversari, C., Ciceri, F., et al. (2007). The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol. Ther. 7, 1248–1252. doi: 10.1038/sj.mt.63 00190

Bonini, C., Bondanza, A., Bondanza, M. T., Bondanza, A., Traversari, C., Ciceri, F., et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719–1724. doi: 10.1126/science.276.5319.1719

Borchers, S., Provasi, E., Silvani, A., Radrizzani, M., Benati, C., Dammann, E., et al. (2003). Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. Hum. Gene. Ther. 7, 829–841. doi: 10.1089/hum.2010.162

Briones, C., and Amils, R. (1998). The evolution of function: a new method to assess the phylogenetic value of ribosomal sensitivity to antibiotics. Int. Microbiol. 4, 301–306.

Ciceri, F., Bonini, C., Marktel, S., Zappone, E., Servida, P., Bernardi, M., et al. (2007). Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109, 4698–4707. doi: 10.1182/blood-2006-05-023416

Ciceri, F., Bonini, C., Stanghellini, M. T., Bondanza, A., Traversari, C., Salomoni, M., et al. (2009). Infusion of suicide gene-engineered donor lymphocytes after human haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet. Oncol. 10, 498–500. doi: 10.1016/S1470-2045(09)70474-9

Contassot, E., Ferrand, C., Angonin, R., Cohen, J. L., de Carvalho, B. M., Lorcher, F., et al. (2000). Ganciclovir-sensitive acute graft-versus-host disease in mice receiving herpes simplex virus thymidine kinase-expressing donor T cells in a bone marrow transplantation setting. Transplantation 69, 503–508. doi: 10.1097/00007890-200002270-00007

Ferrand, C., Robinet, E., Contassot, E., Ciceri, F., et al. (2000). Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum. Gene. Ther. 11, 1151–1164. doi: 10.1089/10430340050015202

Garin, M. L., Garrett, E., Tiberghien, P., Apperley, J. F., Chalmers, D., Melo, J. V., et al. (2001). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97, 122–129. doi: 10.1182/blood.V9 7.1.122

Graftho, S. (1997). Bone marrow transplantation today. Support Care Cancer 2, 27–34. doi: 10.1007/BF035523

Hertenstein, B., Wiesneth, M., Novotny, J., Bunjes, D., Stefanic, M., Heine, B., et al. (1993). Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 56, 1114–1118. doi: 10.1097/00007890-199311000-00013

Herve, P., Flesch, M., Tiberghien, P., Wijdenes, J., Racadot, E., Bordigioni, P., et al. (1992). Phase II-III trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79, 3362–3368.

Horowitz, M. M., Gale, R. P., Sondel, P. M., Goldman, J. M., Kersey, J., Kolb, H. J., et al. (1990). Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555–562.

Kolb, H. J. (2008). Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371–4383. doi: 10.1182/blood-2008-03-0 7794

Kolb, H. J., Schattenberg, A., Goldman, J. M., Hertenstein, B., Jacobsen, N., Arcese, W., et al. (1995). Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041–2450.

Massetelli, G., Nagy, M., Lawang, M., Rosen, O., Genvresse, J., Gecser, G., et al. (2003). Reduced intensity conditioning and prophylactic DLIs can cure patients with high-risk acute leukemias if complete donor chimerism can be achieved. Bone Marrow Transf. 31, 339–345. doi: 10.1038/sj.bmt.17 03859

Mavilio, F., Ferrari, G., Rossini, S., Nobili, N., Bonini, C., Casorati, G., et al. (1994). Peripheral blood lymphocytes as target cells of retroviral-vector-mediated gene transfer. Blood 83, 1988–1997.

Mavroudis, D. A., Read, E. J., Mollodrem, J., Raptis, A., Plante, M., Carter, C. S., et al. (1998). T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogeneic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transf. 21, 431–440. doi: 10.1038/sj.bmt.17 01120

Mercier-Letondal, P., Deschamps, M., Sauce, D., Courtox, J. M., Milpied, N., Lioure, B., et al. (2008). Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coin fused with a T cell-depleted marrow graft: an altered immune response? Hum. Gene. Ther. 9, 937–950. doi: 10.1089/hum.2007.156

Naumov, G. I., Naumova, E. S., and Louis, E. J. (1995). Genetic mapping of the alpha-galactosidase MEL gene family on right and left telomeres of Saccharomyces cerevisiae. Yeast 11, 481–483. doi: 10.1002/yea.3201 10512

Tiberghien, P. (1994). Use of suicide genes in gene therapy. J. Leukoc. Biol. 56, 203–209.

Traversari, C., Marktel, S., Magnani, Z., Mangia, P., Russo, V., Ciceri, F., et al. (2007). The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109, 4708–4715. doi: 10.1182/blood-2006-04-015230

Van Dongen, H. P., Olofsen, E., VanHartevelt, J. H., and Kruyt, E. W. (1999). A procedure of multiple period searching in unequally spaced time series with the Lomb-Scargle method. Biol. Rhythm. Res. 2, 149–177. doi: 10.1076/brhr.30.2.149.1424

Verzeletti, S., Bonini, C., Marktel, S., Nobili, N., Ciceri, F., Traversari, C., et al. (1998). Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow up and improved new vectors. Hum. Gene. Ther. 9, 2243–2251. doi: 10.1089/hum.1998.9.15-2243

Weissinger, E. M., Franz, M., Voss, C., Bonini, C., Kremmer, E., and Kolb, H. J. (2000). Expression of HSV-TK suicide gene in primary T lymphocytes: the dog as a preclinical model. Cytokine Cell. Mol. Ther. 1, 25–33. doi: 10.1007/1089473050515886

Weissinger, E. M., Metzer, J., Dobbelstein, C., Wolff, D., Schleuning, M., Kuzmina, Z., et al. (2013). Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia 28, 842–852. doi: 10.1038/leu.2013.210
Weissinger, E. M., Schiffer, E., Hertenstein, B., Ferrara, J. L., Holler, E., Stadler, M., et al. (2007). Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 109, 5511–5519. doi: 10.1182/blood-2007-01-069757

Conflict of Interest Statement: MolMed is a industrial partner, some of the authors are associated with MolMed (as indicated by affiliation).

Copyright © 2015 Weissinger, Borchers, Silvani, Provazi, Radrizzani, Beckmann, Benati, Schmidtle, Kuehnau, Schweier, Luther, Fernandez-Munoz, Beutel, Cicero, Bonini, Ganser, Hertenstein and Stadler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.